December 11, 2018
Authored and Edited by Megan L. Meyers; M. Andrew Holtman, Ph.D.
On December 3, 2018, FDA issued final guidance on Post-Complete Response Letter (CRL) Meetings between FDA and ANDA Applicants under GDUFA. The guidance provides recommendations to industry on post-CRL meetings between FDA and ANDA applicants for the purpose of clarifying deficiencies identified in a CRL to an ANDA submitted under section 505(j) of the FDCA. FDA defines a post-CRL meeting as a meeting requested in writing by an ANDA applicant pursuant to procedures described in the guidance following receipt of a CRL. This guidance is intended to provide procedures that will promote a well-managed post-CRL meeting.
FDA will grant any complete post-CRL meeting request that satisfies the criteria outlined in section IV of the guidance. The written request should be submitted to the ANDA via Electronic Submissions Gateway within 10 calendar days of issuance of the CRL. Any post-CRL meeting request should include the following information:
The guidance further specifies the grant and denial process of the post-CRL meeting request, as well as the action to be taken by FDA or requestor following the decision.
Readers are encouraged to read the final guidance.
Copyright © 2018 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.